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The classification of mononuclear phagocytes as either dendritic cells or macrophages 
has been mainly based on morphology, the expression of surface markers, and assumed 
functional specialization. We have recently proposed a novel classification system of 
mononuclear phagocytes based on their ontogeny. Here, we discuss the practical 
application of such a classification system through a number of prototypical examples 
we have encountered while hitchhiking from one subset to another, across species and 
between steady-state and inflammatory settings. Finally, we discuss the advantages and 
drawbacks of such a classification system and propose a number of improvements to 
move from theoretical concepts to concrete guidelines.
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introduction
In the science fiction series created by Douglas Adams (1), the Hitchhiker’s Guide to the Galaxy 
starts as follows: “Space is big. Really big. You just won’t believe how vastly hugely mind-boggling 
big it is. You may think it’s a long way down the road to the chemist’s, but that’s just peanuts to 
space.” Given the complexity of the mononuclear phagocyte (Star)system (MPS), one could easily 
give a similar warning to readers who are trying to make some sense of the huge number of hypo-
thetically distinct dendritic cell (DC) and macrophage (MΦ) subsets. At the last International 
DC Symposium (DC2014, Tours  –  France), we counted at least 28 different DC subsets that 
were described using various surface markers and nomenclature systems in distinct species. 
If one would add the different MΦ subsets and the Cytof technology allowing to measure the 
expression of more than 30 different surface markers per cell, one could with a bit of luck end 
up with “42” as answer to the ultimate myeloid question of how many mononuclear phagocyte 
subsets exist in life, the universe, and everything. Although this would be great for fans of 
Douglas Adams, without Babel Fish to help us make some sense of so many different subsets, 
this evolution will not be beneficial for communication among myeloid cell experts, let alone 
for the communication toward pharmaceutical companies, scientific editors, medical doctors, 
or graduate students. We will here try to simplify this apparent complexity through a number of 
practical examples and theoretical concepts. Having hitchhiked from MΦ to DC labs studying 
myeloid cells in various tissues and in distinct inflammatory conditions, we would, in accord-
ance with the Hitchhiker’s Guide to the Galaxy, advise the following: do not panic and bring 
your towel along.
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Members of the Mononuclear  
phagocyte system
In the original MPS model proposed by Ralph van Furth, James 
Hirsch, and Zanvil Cohn, MΦs were proposed to derive from cir-
culating monocytes (2). A couple of years later, Ralph Steinman 
and Zanvil Cohn identified DCs, which were also included in the 
MPS (3). The fact that DCs could be derived from human and 
mouse monocytes in GM-CSF-driven in vitro cultures (4–8) and 
in vivo upon inflammation or in barrier tissues (9–15) supported 
this concept. For a historical overview of the MPS field, we redi-
rect the readers to the review of Simon Yona and Siamon Gordon 
in this issue (16). The identification of mouse hematopoietic 
precursors committed to the DC lineage called the common DC 
progenitors (CDPs  –  giving rise to pDCs and cDCs) and pre-
cDCs (giving rise to cDCs) that are distinct from monocytes and 
can give rise to the so-called conventional DCs (cDCs) induced 
a first conceptual revolution in the field (12, 17–20). Moreover, 
Flt3-L, and not GM-CSF, was shown to be critically involved in 
the development of cDCs in vitro (8, 21–23) and in vivo (24–28). 
Recently, two additional committed precursors were identified in 
mice: the pre-pDC precursor that preferentially differentiates into 
pDCs (29), and the monocyte-committed common monocyte 
progenitor (cMop) (30). Importantly, the human equivalent of 
the pre-cDC, CDP, and cMop was recently identified (31, 32). 
A second conceptual revolution in the field was driven by the 
finding that most tissue-resident MΦs do not derive from cir-
culating HSC-derived monocytes but develop from embryonic 
precursors, i.e., the yolk-sac MΦs (YS MΦs) or fetal liver (FL) 
monocytes (33–39). The relative contribution of YS MΦ-derived 
and FL monocyte-derived MΦs seems to vary from one organ 
to another (40–42). It was recently demonstrated that almost all 
MΦs have a YS origin [either directly from YS MΦs or through 
YS-derived EMPs (39)]. This may seem in contradiction with the 
proposed partial origin from FL monocytes (35, 43). However, it 
is now clear that YS-derived EMPs seed the FL and go through a 
FL monocyte intermediate before differentiating into most tissue-
resident MΦs (44), reconciling most of the apparent discrepan-
cies in the field. Together, these findings have challenged the MPS 
dogma and revealed that most DCs and MΦs derive from distinct 
committed precursors rather than from circulating HSC-derived 
monocytes (Figure 1).
revisiting the Classification of 
Mononuclear phagocytes
Historically, mononuclear phagocytes were classified as DCs or 
MΦs based on a restricted set of surface markers (CD11c and 
MHCII for DCs versus F4/80 for MΦs), proposed functional 
specialization (antigen-presentation and migration to lymph 
nodes for DCs versus phagocytosis for MΦs) and/or morpho-
logical features (dendritic-shaped cells for DCs versus large 
vacuolar cells for MΦs). However, these features are often not 
mutually exclusive. For example, although CD11c and MHCII 
are typically associated with DCs, alveolar MΦ are CD11chi and 
MHCII is expressed by intestinal MΦs (35, 45). Ideal surface 
markers allowing identification of the distinct myeloid cell 
subsets across tissues and species are still incomplete. Markers 
typically associated with some myeloid cell subsets can be 
lost or acquired by other subsets. The monocyte-associated 
FiGUre 1 | Mononuclear phagocytes and their precursors. Note that this is work in progress and technical advances such as single-cell RNASeq and 
barcoding will in the near future prove or disprove many aspect of this theoretical scheme.
FiGUre 2 | a nomenclature system in two levels would have the 
advantage that cells can be first classified based on a restricted set of 
names (in this proposition according to their cellular origin: MΦ, MC, 
cdC1, cdC2, pdC) that would be applicable across species and across 
tissues, but the second level would still allow some flexibility to denote 
a distinct activation state or localization.
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marker Ly-6C is rapidly down-regulated on many monocyte-
derived cells (MCs) upon entrance in the tissues (45–48) and is 
expressed on pDCs (and lowly expressed on some cDCs). The 
pDC-associated marker mPDCA1 (stained with 120G8) can be 
acquired by MCs during inflammation (49). Alveolar MΦs (50) 
and Kupffer Cells (unpublished data) can upregulate CD11b 
during inflammation. Finally, BDCA3 is expressed on both 
human cDC1s and MCs (51). Thus, the inability to consistently 
identify myeloid cell subsets irrespective of tissue, species, or 
inflammatory state makes surface markers unattractive as basis 
for classification.
We would also propose to avoid a classification based primar-
ily on functional specialization. First, each myeloid cell subset 
can perform more than one prototypical function. MΦs are often 
linked to phagocytosis of dead cells and pathogens but also have 
important immunomodulatory and metabolic functions. Second, 
subsets can acquire or lose functional capacities during inflam-
mation as recently demonstrated for cDC2s that acquire cross-
presentation capacities upon TLR stimulation (52). Therefore, we 
propose to disregard function as a basis for classifying cells.
Instead of surface markers, functional specialization, or mor-
phology, we have recently suggested to classify cells based on their 
cellular origin, which could allow a more robust classification 
system (53). This would yield three big groups of cells (Figure 1): 
(i) embryonic progenitor-derived MΦs, (ii) CDP-derived DCs 
(that would be subdivided into cDC1s, cDC2s, and pDCs), and 
(iii) MCs. As these precursors have now been identified in both 
the mouse and the human, this allows one classification system 
across tissues and species.
Although precursor-based classification would provide a 
robust and species-conserved system, at the end of the day the 
function of the cells is what really matters for converting our 
knowledge into therapeutic advances for patients. Regrouping all 
the DCs into three big subsets of cDC1s, cDC2s, and pDCs will 
thus have the disadvantage of lumping together cells that may 
be in very different functional activation states. Similarly, MCs 
have been shown to be particularly plastic cells (54). Therefore, 
we propose to add a second classification level to the fixed 
ontogeny-based Level1 (Figure 2). Addition of a Level2 allows 
specification of the cellular activation state, the micro-anatomical 
localization or simply the surface markers utilized to identify the 
cells in a particular study. Of note, when defining the Level2 it 
will be important to avoid generalizations as a given function is 
often performed by only a fraction of the cells studied. We would 
thus propose to restrict the Level2 to objective criteria that can be 
measured at the single-cell level.
practical implementation for dCs
Historically, DCs were divided into subsets based on surface 
markers that differed between tissues and species, such as CD207 
(Langerin) in the skin, CD103 (IntegrinαE) in the intestine, 
CD11b (IntegrinαM) in the lungs, CD4/CD8α in the spleen, and 
CD24/CD172α for in vitro differentiated DCs (Figure 3). Human 
DCs, on the other hand, have been divided into CD141+ (BDCA3) 
and CD1c+ (BDCA1) DCs. pDCs are identified by the expres-
sion of BDCA4 and BDCA2 in human, but by B220, mPDCA1 
(BST2, recognized by 120G8), or Siglec-H in mice (53). Technical 
advances in multi-color flow cytometry have made matters worse 
with evermore “novel DC subsets” based on the expression of 
additional surface markers. By comparing the gene-expression 
profile of DCs isolated from various tissues and species, one can 
appreciate three big clusters of DCs (55–61). The pDC cluster 
includes mouse PDCA1+ pDCs and human BDCA2+BDCA4+ 
pDCs. The cDC1 cluster comprises dermal CD207+CD103+ 
cDC1s, lung CD103+CD11b−cDC1s, splenic CD8a+CD4− cDC1s, 
intestinal CD103+CD11b− cDC1s and human blood BDCA3+ 
cDC1s. Dermal CD207−CD11b+ cDC2s, lung CD103−CD11b+ 
cDC2s, splenic CD8a−CD4+ cDC2s, intestinal CD103+CD11b+ 
cDC2s and human blood BDCA1+ cDC2s form the cDC2 
cluster (62, 63). This bio-IT-driven analysis also revealed that 
within the cDC population, XCR1 and Sirpα are, respectively, 
expressed by all cDC1s and cDC2s across tissues, allowing an 
improved identification of these cells (51, 64–70). Note, however, 
that Sirpα is also expressed by other myeloid cells than cDC2s, 
showing the need for correct cDC identification prior to using 
this marker to distinguish cDC2s from cDC1s. Strikingly, this 
gene-expression-based division is supported by the existence of 
distinct pre-committed precursors (29, 71, 72) and by differen-
tial developmental transcription factor requirement of cDC1s, 
FiGUre 3 | Murine dCs have been subdivided into many different 
subsets based on distinct surface markers in the spleen, the skin, the 
intestine, and the lung.
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cDC2s, and pDCs in the mouse. cDC1s, but not cDC2s, require 
BATF3 (71, 73, 74), ID2 (28, 75, 76), NFIL3 (77), and IRF8 (28, 
71, 78–80) for their development, while cDC2s, but not cDC1s, 
are dependent on RELB (81), RBPJ (82), and IRF4 (79, 83–85). 
pDC development has been shown to be driven by E2-2 (86, 87).
The subdivision of DCs in three distinct Level1 groups is 
thus supported by their gene-expression profiles, cellular origin, 
and transcription factor requirement. However, these cells can 
acquire a distinct functional activation state from one tissue to 
another and in distinct inflammatory settings, underlining the 
need for a Level2 system. This can be illustrated by the capacity of 
intestinal cDCs to produce retinoic acid and promote the genera-
tion of induced regulatory T cells (iTREGs) (88–91). Identification 
of DCs with superior iTREG inducing ability is clinically relevant as 
the prevalence of food allergies, celiac disease and inflammatory 
bowel diseases is currently rising throughout the western world. 
Originally, it was described that CD103+ but not CD103− intes-
tinal DCs excel in iTREG generation in a retinoic acid-dependent 
manner (89, 90). It is now clear that CD103+ intestinal DCs com-
prise two ontogenically distinct subsets, CD103+CD11b− cDC1s 
and CD103+CD11b+ cDC2s (74). Interestingly, rather than being 
associated with either of the two subsets, about half of the intesti-
nal CD103+CD11b− cDC1s were shown to possess the capacity to 
produce retinoic acid, while only one-third of the cDC2s do (91). 
Moreover, on a per cell basis retinoic acid producing CD103+ 
cDC1s were the best at inducing iTREGs (Figure  4). These data 
reveal that CD103+ cDC1s, although broadly considered as a 
homogeneous subset, consist of 50% cells that are very efficient 
at inducing iTREGs and 50% cells that are not. Interestingly, dermal 
cDC2s have higher retinoic acid-dependent iTREG induction 
activity than dermal cDC1s (91). We hypothesize that this func-
tional heterogeneity may be explained by the existence of distinct 
micro-environments within organs, inducing diverse functional 
modules on DCs. The finding that important functional modules 
can be acquired by only a fraction of cDC1s and/or cDC2s, which 
can moreover differ from one organ to another, illustrates the 
need for a Level2 nomenclature for DCs.
Another example of functional heterogeneity within DCs 
concerns the cDC2s. Splenic cDC2s contain a subpopulation that 
expresses CD4 and is specifically localized in the bridging chan-
nels (92). This localization has been shown to be EBI2-driven and 
essential to drive antibody production by B cells. The develop-
ment of these CD4+ cDC2s is Notch2 dependent. Note also that 
Notch2 deficiency is associated with defects in TH17 induction 
(93, 94). In addition, it was found that KLF4 controls the develop-
ment of a subpopulation of CD24loCD11bloSirpαhi cDC2s in the 
dermis (95). Importantly, loss of KLF4 was associated with loss 
of TH2 induction. Thus, although cDC2s have been proposed to 
excel at both the induction of TH2 (47, 96) and TH17 responses 
(84, 85, 93), it may well be that these functional modules are in 
fact expressed by subpopulations of cDC2s (controlled by KLF4 
and Notch2, respectively). In conclusion, although the current 
knowledge of early DC development in the bone-marrow seems 
to support only three big groups of DCs (cDC1s, cDC2s, and 
pDCs), it appears that a second layer of tissue-specific signals 
imprint operative gene modules on a fraction of DCs. Depending 
on their micro-localization, subpopulations of cDC1s, cDC2s, 
or pDCs will acquire distinct functional properties, requiring 
a flexible Level2 to classify and describe functionally distinct 
subpopulations.
A final example of a need for a Level2 classification involves 
inflammation-induced changes of surface marker expression. 
When mice are infected with the influenza virus, there is a 
transient change in the CD103 versus CD11b expression profile 
of lung cDCs, yielding four instead of two lung DC subsets 
(Figure 5). If one considers these as four distinct DC subsets, one 
could conclude that influenza infection disrupts hematopoiesis in 
the bone-marrow, as has been shown for Toxoplasma infection 
(97). Alternatively, these novel CD103/CD11b expression pat-
terns may represent distinct local activation states of cDC1s or 
cDC2s. We have studied the cellular origin of the “novel” DC sub-
sets arising during influenza infection (Neyt et al., manuscript in 
preparation). Our preliminary data suggest that CD103+CD11b+ 
cells are cDC2s that acquire CD103 expression during inflamma-
tion rather than a completely new subset. In conclusion, although 
we cannot rule out the existence of additional DC subsets that 
specifically develop during inflammation, when in doubt we pro-
pose to first evaluate whether cells with a novel surface receptor 
expression profile represent a different activation state of cDC1s 
or cDC2s before assuming the existence of a novel cDC3.
practical implementation for embryonic 
Macrophages
In our classification system based on ontogeny all mononuclear 
phagocytes of embryonic origin are grouped together under 
a single Level1 as “macrophages” (Figure  1). This includes 
liver-resident Kupffer cells, brain-resident microglial cells, lung-
resident alveolar MΦs but also epidermis-resident Langerhans 
cells. In effect, this would thus classify Langerhans cells as MΦs 
and not as DCs, based on the fact that these cells derive from 
embryonic precursors that seed the epidermis around birth 
and then self-maintain throughout life (43, 98). We propose to 
keep the historical names for MΦs with undisputed identities. 
Mouse Kupffer cells, for example, do not require a different 
nomenclature since these cells have a well-defined cellular 
origin [embryonic (34, 38, 39)], localization (i.e., the liver 
sinusoids), and gene-expression profile (99, 100). However, 
we would like to emphasize that not any F4/80+ cell in the 
liver should be categorized as Kupffer cell. MCs infiltrating 
FiGUre 4 | existence of subpopulations with distinct retinoic acid-
producing capacities within both cdC1s and cdC2s in the mesenteric 
lymph nodes of mice. The capacity to produce retinoic acid was measured 
by the Aldefluor kit (91). DCs were sorted, loaded with the ovalbumin-peptide, 
and co-cultured in vitro with naïve OTII cells to measure the induction of Foxp3 
on these cells.
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the liver during acetaminophen-induced injury also express 
F4/80 but are short-lived and acquire a gene-expression 
profile that is strikingly different from resident Kupffer cells 
(100). Similarly, MCs infiltrating the central nervous system 
during inflammation are short-lived and do not acquire the 
specific gene-expression profile of embryonic microglia 
(101–103). As such, any MΦ-like cell in the liver or the 
brain should not be classified as Kupffer cell or microglia, 
respectively, as is often the case. Unfortunately, tools to cor-
rectly distinguish MCs from resident MΦs have long been 
lacking. In a way, this is surprising given the huge difference 
in gene-expression profile between resident embryonic MΦs 
and recruited MCs in these disease models. We have now 
identified several surface markers that are expressed by 
Kupffer cells but not MCs recruited during liver injury (Scott 
et  al. manuscript in preparation) and we expect that given 
the striking heterogeneity of tissue-resident MΦs (104, 105) 
many of these MΦ-specific markers will be found. This will 
facilitate the correct classification of these cells and pave the 
way toward unraveling the functional differences between 
recruited MCs and tissue-resident embryonic MΦs during 
inflammation.
practical implementation for  
Monocyte-derived Cells
Monocytes are particularly plastic cells. This can be appreci-
ated using in  vitro culture systems. Monocytes cultured 
with GM-CSF express some DC-like characteristics and 
have therefore long been referred to as moDCs. By contrast, 
culturing monocytes with M-CSF induces their differentiation 
into MΦ-like cells (moMΦs). Adding IL-4 or IFN-γ to M-CSF 
cultures further polarizes MCs into the so-called “classically 
activated MΦs/M1s” or “alternatively activated MΦs/M2s” 
(106), with strikingly different gene-expression profiles and 
metabolic modules (107). In a nomenclature system based on 
ontogeny, moDCs, M1s, or M2s are however first classified as 
MCs (Level1). In theory, this does not prevent further Level2 
classification as “dendritic MCs,” “classically activated MCs,” or 
“alternatively activated MCs.” However, we feel this polarized 
classification implies functional characteristics that are often 
not assessed experimentally. For example, MCs classified as M1s 
are typically associated with pathogen killing, M2s with wound 
healing, and moDCs with antigen-presentation (Figure  6). 
However, the identification of “dendritic MCs/moDCs,” “classi-
cally activated MCs/M1s,” or “alternatively activated MCs/M2s” 
in vivo turned out to be very challenging. In fact, profiling of 
MCs isolated from various inflamed tissues or in vitro culture 
systems reveals that monocytes can acquire a much broader 
transcriptional repertoire than suggested by the three-way M1/
M2/moDC model. In recent efforts to further characterize the 
heterogeneity of MC activation states, Schultze and colleagues 
compared the gene-expression profile of MCs stimulated with 
a vast array of cytokines and TLR ligands. Instead of yielding 
a polarized model, the unbiased bio-informatics-driven clus-
tering approach revealed a spectrum model (54). In our view, 
this spectrum model can be taken one step further and include 
the “dendritic MCs/moDCs” derived from GM-CSF-induced 
bone-marrow cultures as yet another extreme of the continuum 
of cellular faiths that can be acquired by monocytes. Rather 
FiGUre 5 | inflammation can induce the appearance of “novel” dC subsets. CD103 and CD11b expression on cDCs from uninfected or influenza-infected 
lungs are shown. The appearance of CD103+CD11b+ DCs and CD103−CD11b− DCs is transient as schematically represented.
FiGUre 6 | a modular spectrum model for monocyte-derived cells. Replacement of the polarized three-way M1/M2/moDC model by a spectrum model in 
which bacterial killing, wound-healing, and antigen-presentation represent only three of many functional modules that can be acquired by MCs.
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than unique end points, bacterial killing, wound-healing, and 
antigen-presentation represent three of many functional mod-
ules that can be acquired by MCs in a spectrum model that can 
be graphically represented by a continuous circle (Figure 6).
One important consequence of the herein-described clas-
sification would be the regrouping of moDCs and moMΦs under 
a single MC Level1. We feel this will represent an improvement 
for the field due to the lack of clear, mutually exclusive features 
FiGUre 7 | Microscopic characterization of MCs isolated from inflamed mesenteric lymph nodes in an experimental model for colitis. 
CD11chiMHCIIhiCD64hiF4/80hi cells were sorted and cultured in vitro to evaluate their morphology and capacity to phagocytose latex beads (45).
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that can be used to objectively separate moDCs from moMΦs 
(53). This problem can be illustrated by the MCs present within 
inflamed mesenteric lymph nodes during an experimental model 
for colitis (45). In this study, we called these cells moMΦs because 
they were CD64hiF4/80hi and excelled at phagocytosis (Figure 7). 
However, we could perfectly, like the Powrie group (108), have 
classified these cells as moDCs based on their CD11chiMHCIIhi 
profile, their localization within the T cell zone, their antigen-
presentation capacity, or their dendritic morphology (Figure 7). 
By classifying these cells as CD64hiF4/80hi and/or CD11chiMHCIIhi 
MCs, they are recognized as one lineage, which will promote 
understanding and simplify communication between different 
research groups without preventing the study of DC-like or MΦ-
like properties of specific MCs.
Finally, we do not expect MCs to be homogeneous in inflamed 
tissues. We and others found iNOS, the enzyme that is used by 
MΦs to produce NO and that is classically associated with an M1 
activation state, to be typically expressed by only 10% of MCs (11, 
45, 109). Since NO is bactericidal, suppressive for T cells, and can 
induce serious tissue damage, it makes perfect sense to study the 
factors that induce the expression of iNOS on a fraction of MCs. 
But by classifying these cells as “iNOS+ MCs” instead of “M1 
macrophages” or “TIP-DCs” one avoids to associate functions 
that have not been proven for these cells such as the antigen-
presentation activity typically expected from DCs [in fact mice 
lacking monocytes showed identical T cell priming suggesting 
that TIP-DCs are not essential for this function (11)].
the tough Cases part i: modCs as  
Fourth dC subset?
MCs fitting the complete list of characteristics attributed to moDC, 
including migratory and antigen-presentation capacities compa-
rable to cDCs, are not easily identified in vivo. We have described 
migratory MCs upon house-dust mite (HDM) exposure in the 
lungs (47), but their migration is much less efficient as compared 
to cDCs and required very high (and non-physiological) doses 
of HDM. In fact, we found that the majority of HDM-induced 
pulmonary MCs are not migratory cells but instead play an 
important role in the secretion of inflammatory chemokines that 
orchestrate the local immune responses. Similarly, a low-grade 
migration of CCR2+CD64int MCs was described upon DSS 
inflammation in the skin but this was minor as compared to 
cDC migration (48). Moreover, compared to cDCs these dermal 
CCR2+CD64int MCs displayed a rather modest antigen–antigen 
presentation capacity.
The most convincing pieces of evidence for cDC-like features 
of MCs come from in  vitro culture systems. Bone-marrow 
cells cultured with GM-CSF yield cells with excellent antigen-
presentation capacity that acquire CCR7, the chemokine recep-
tor controlling migration of cDCs from tissues to lymph nodes, 
upon TLR stimulation and can migrate to the lymph nodes upon 
in vivo transfer (110, 111). This culture system has been used in 
many labs and is globally accepted to yield a homogeneous popu-
lation of moDCs. This concept was first challenged by a study 
using single-cell transcriptomics (112). Among LPS-stimulated 
GM-CSF-induced bone-marrow-derived moDCs, the majority of 
cells were found to show high expression of inflammatory genes 
such as TNF, IL1, and CXCL10, while a smaller subset had much 
lower expression of these genes but displayed a signature reminis-
cent of “mature DCs,” including high expression of CCR7 (113, 
114). This was originally interpreted as functional heterogeneity 
among moDCs. However, in what we consider a landmark paper, 
Reis e Sousa and colleagues now demonstrate that this minor 
“mature” population in fact represents cDC2s that contaminate 
these cultures. These cDC2s displayed lower production of inflam-
matory cytokines but much better CCR7-ligand-induced migra-
tion and antigen-presentation as compared to GM-CSF-induced 
MCs (115, 116). This implies that many of the DC-like features 
of GM-CSF-induced moDCs should in fact not be attributed to 
MCs, but to a minor contaminating cDC2 population. All in all, 
both in vitro and in vivo data thus point toward a lower migration 
and antigen-presentation capacity of MCs as compared to cDCs, 
but conversely a higher production of inflammatory cytokines 
and chemokines. We therefore propose that in an inflamed organ 
the core business of cDCs will be migration to the draining lymph 
nodes and activation of naïve T cells, whereas MCs will primarily 
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orchestrate local inflammatory responses. Note that this has 
important consequences for DC-based vaccination strategies as 
this may explain why MC-based vaccines have only yielded mod-
est clinical responses (117). The recent advances in cDC culture 
systems and the proper identification of committed circulating 
DC-precursors (31, 32, 118) may therefore pave the way toward 
more efficient cDC-based vaccination strategies.
the tough Cases part ii: steady-state 
MCs Versus embryonic Macrophages
Most MΦ-like cells present in steady-state tissues are of embry-
onic origin (33–36, 38, 39, 44). However, puzzling exceptions 
have been reported. Although embryonic MΦs colonize the 
intestine and the heart before birth, these cells are thereafter pro-
gressively replaced by MCs. Importantly, these cells are relatively 
short-lived and continuous monocyte-recruitment is required to 
maintain the MC pool in these tissues (45, 46, 119–121). Similarly, 
monocytes are continuously recruited to the steady-state dermis 
(48). Therefore, while in some steady-state tissues, including the 
lung and the spleen, monocytes have been proposed to remain in 
an undifferentiated state (37, 122); in others, including the intes-
tine, the skin, and the heart, they acquire a MΦ-like phenotype. 
The classification of MCs that differentiate in these steady-state 
organs and that replace the embryonic MΦs is difficult. They 
do not fit the profile of the MCs that are recruited to inflamed 
tissues, including pulmonary infection (36), auto-immune brain 
inflammation (101, 102), and acute liver injury (100), since in 
these inflammatory settings MCs do not replace the embryonic 
MΦs and display a very different gene-expression profile. Future 
research will be required to compare the functional properties 
and gene-expression profile of the embryonic MΦs present in the 
intestine, the skin, and the heart to the ones from the MCs that 
replace them with time. It will be interesting to compare the influ-
ence of tissue-imprinting to the intrinsic differences associated 
with their distinct cellular origin. Embryonic MΦs were recently 
compared to their bone-marrow-derived counterparts that 
replace them after irradiation-induced depletion. It was found 
that both cells share between 50 and 90% of the tissue-specific 
epigenetic landscape (105). This emphasizes the importance of 
tissue-imprinting, but at the same time implies that between 10 
and 50% of the epigenetic landscape could be governed by the 
cellular origin of the cells. Future research will be required to 
assess the functional relevance of these findings. In the meantime, 
the classification of MΦ-like MCs in steady-state tissues remains 
difficult.
the Way Forward
The Level1 that forms the scaffold of the herein proposed clas-
sification system is in part based on elegant murine fate-mapping 
systems developed to study the cellular origin of MΦs (33, 34, 
38, 39, 43, 44) and DCs [(123) and (124) in this issue]. Although 
the recent identification of committed DC-precursors distinct 
from monocytes in humans suggests that many of the principles 
identified in mice apply to the human immune system, this 
remains to be formally proven. Moreover, many of these murine 
fate-mapping systems label only a small fraction of the cells per 
population, rendering functional studies difficult. In cases where 
classification as cDC1, cDC2, pDC, MC, or MΦ is not obvious, a 
core set of signature genes that are specific for each cell type could 
facilitate correct Level1 identification. However, such signature 
genes are not easily identified. In addition, identification based 
on surface receptors would be most practical since it would allow 
the sorting of living cells through flow cytometry for functional 
assays. Ideally, such markers would be conserved across species. 
We are currently data-mining the gene-expression profiles of cells 
from various tissues and species to try to identify such markers. 
This can however represent a catch22. To find markers specifically 
expressed by the different populations, one requires pure gene-
expression profiles, but correct sorting of the cells without con-
tamination by other populations for RNA profiling requires the 
very markers we are looking for. Recent technological advances in 
single-cell RNA sequencing will allow to profile the gene expres-
sion of mixed populations. This may at last disentangle mixed 
myeloid populations and will hopefully provide the field with new 
markers that can then be validated with the current fate-mapping 
systems.
Although the current classification systems should thus be 
seen as work in progress, we are confident that in the near future 
better markers will be found which faithfully translate the cel-
lular origin of cells and will form a practical base for the Level1 
classification of myeloid cells. The Level2 classification should 
in our view be kept as flexible as possible to allow researchers 
to focus on one particular functional attribute of their cells of 
interest without implying too many additional features that have 
not been studied. Finally, it is noteworthy that in parallel to our 
proposition a nomenclature system for MΦs was proposed (106). 
In this proposition, terms implying functional specialization such 
as “classically activated macrophages” (pro-inflammatory) or 
“alternatively activated macrophages” (anti-inflammatory) were 
replaced by an objective description of how a MΦ is cultured 
in  vitro [e.g., MΦ (IL-10)] or identified in  vivo (e.g., “Relmahi 
MΦ”). Thus, the common core Level1 would be MΦ and the 
added description provides the Level2. This and our classification 
system thus share three important principles: (i) elimination of 
terms that imply functional specialization as much as possible, 
(ii) introduction of a fixed Level1 system across species and 
tissues, and (iii) permitting flexibility through a Level2 system. 
Irrespective of which system is used to define the Level1 [ontog-
eny as we propose, or gene-expression profile as proposed by the 
Dalod group in this issue (60, 61)], we feel these three principles 
should be maintained for a future and hopefully definitive clas-
sification system.
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